8 Supplements Ranked for Reversing Artery Plaque — Only One Holds Up
Simon Hill ranks 8 popular supplements by human evidence for reversing atherosclerosis — one stands far above the rest.
Summary
In this solo episode, Simon Hill reviews eight supplements commonly promoted for reversing arterial plaque and ranks them strictly by human clinical evidence. Pure EPA omega-3 emerges as the clear frontrunner, supported by the EVAPORATE trial showing 9% plaque regression and REDUCE-IT demonstrating a 25% reduction in cardiac events. Aged garlic extract and vitamin K2 show modest but intriguing imaging data. Niacin, despite raising HDL, failed to reduce events in major trials. CoQ10, berberine, nattokinase, and pomegranate extract round out the list with limited or conflicting human evidence. Hill also shares his personal protocol after discovering early plaque in his own coronary artery, and cautions that supplements are adjuncts — never replacements — for proven lifestyle and pharmaceutical interventions.
Detailed Summary
Atherosclerosis, the buildup of plaque in arterial walls, remains the leading cause of cardiovascular death globally. The question of whether supplements can not merely slow but actually reverse this process is one of the most frequently asked in preventive cardiology — and one that has become personal for host Simon Hill, who discovered early plaque in his left anterior descending artery on a 2024 scan.
In this evidence-ranked review, Hill evaluates eight supplements against the standard of human imaging and outcomes data. Pure EPA omega-3 (icosapentaenoic acid) sits alone at the top tier. The EVAPORATE trial demonstrated a 9% regression in low-attenuation plaque with 4g/day of pure EPA, while JELIS and REDUCE-IT showed meaningful reductions in cardiovascular events. Hill also addresses the ongoing REDUCE-IT versus STRENGTH controversy, noting that the form and purity of omega-3 may matter as much as dose.
Aged garlic extract and vitamin K2 occupy a second tier, with small but reproducible signals in imaging studies on plaque progression and arterial calcification respectively. Vitamin K2's proposed mechanism — redirecting calcium away from arterial walls — is biologically plausible but not yet proven at the outcomes level.
Niacin serves as a cautionary tale: robust HDL elevation without mortality benefit in large trials like AIM-HIGH and HPS2-THRIVE. CoQ10 has a credible antioxidant mechanism but lacks plaque imaging data. Berberine operates via a unique gut-mediated pathway and shows lipid benefits, though plaque regression data are thin. Nattokinase yields strikingly contradictory results across two trials — one showing a 36% plaque drop, another showing zero effect. Pomegranate extract has compelling animal data that has not translated to humans.
Hill concludes that only prescription-grade EPA has strong supporting evidence, and even that requires medical supervision. Lifestyle fundamentals remain primary; supplements are at best targeted adjuncts.
Key Findings
- Pure EPA at 4g/day regressed coronary plaque by 9% in the EVAPORATE trial and cut cardiac events 25% in REDUCE-IT.
- Aged garlic extract and vitamin K2 show modest imaging signals but lack large outcomes trial confirmation.
- Niacin raises HDL robustly yet failed to reduce cardiovascular events or mortality in major RCTs.
- Nattokinase evidence is directly contradictory — one trial shows 36% plaque reduction, another shows none.
- No supplement reviewed replaces lifestyle or pharmaceutical therapy; pure EPA requires a prescription form for efficacy doses.
Methodology
This is a narrative evidence review presented as a podcast episode, not an original study. Hill synthesizes data from named clinical trials including EVAPORATE, REDUCE-IT, STRENGTH, JELIS, VITAL, AIM-HIGH, and HPS2-THRIVE, ranking supplements by the strength of human imaging and outcomes evidence rather than mechanistic or animal data alone.
Study Limitations
This is a podcast review by a science communicator, not a peer-reviewed meta-analysis, and reflects one host's interpretation of selected trials. Sponsorship relationships are present and disclosed. The summary is based on the published episode abstract and chapter timestamps only, without access to a full transcript or cited references.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: